Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge J Castillo

Showing results (291-300 of 343) with videos related to

Pageof 35
Sort By:
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
Blood|February 24, 2016
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemiaAldo M Roccaro, Antonio Sacco, Jiantao Shi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.
Leukemia & Lymphoma|July 7, 2020
Primary refractory multiple myeloma: a real-world experience with 85 casesArtur Jurczyszyn, Anna Waszczuk-Gajda, Jorge J Castillo, et al.
Leukemia & Lymphoma|January 5, 2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patientsArtur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's MacroglobulinemiaRamón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, et al.
Pageof 35

Showing results (291-300 of 343) with videos related to

Sort By:
Pageof 35
Blood|June 16, 2021
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistanceGuang Yang, Jinhua Wang, Li Tan, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
British Journal of Haematology|April 20, 2025
Development and characterization of the novel MYD88 mutated, 6q deleted BCWM.2 cell line for Waldenström macroglobulinaemiaShirong Liu, Xia Liu, Choudhury Fabliha Binte Yusuf, et al.
Blood|February 24, 2016
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemiaAldo M Roccaro, Antonio Sacco, Jiantao Shi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2020
Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment StrategiesSteven P Treon, Lian Xu, Maria Luisa Guerrera, et al.
Blood|July 21, 2021
Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemiaSteven P Treon, Kirsten Meid, Zachary R Hunter, et al.
Leukemia & Lymphoma|July 7, 2020
Primary refractory multiple myeloma: a real-world experience with 85 casesArtur Jurczyszyn, Anna Waszczuk-Gajda, Jorge J Castillo, et al.
Leukemia & Lymphoma|January 5, 2016
Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patientsArtur Jurczyszyn, Magdalena Olszewska-Szopa, Vania Hungria, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2021
Venetoclax in Previously Treated Waldenström MacroglobulinemiaJorge J Castillo, John N Allan, Tanya Siddiqi, et al.
Seminars in Hematology|April 26, 2023
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's MacroglobulinemiaRamón Garcia-Sanz, Marzia Varettoni, Cristina Jiménez, et al.
Pageof 35